首页> 外文期刊>Hematology >Pathogenicity analysis of variations and prenatal diagnosis in a hereditary coagulation factor XIII deficiency family
【24h】

Pathogenicity analysis of variations and prenatal diagnosis in a hereditary coagulation factor XIII deficiency family

机译:遗传性凝血因子XIII缺乏症家族变异的病原性分析和产前诊断

获取原文
           

摘要

Objectives: Prenatal diagnosis (PND) procedure is urgent to be established for timely management and fatal consequence prevention of factor XIII deficiency (FXIIID), and variations data among Chinese are very scanty. We aimed to find a novel mutation among Chinese and establish a rapid and precise PND procedure with pathogenicity analysis to contribute to the prevention of postpartum hemorrhage in pregnant women and central nervous system bleeding in newborns. Methods: FXIIID was diagnosed by qualitative and quantitative tests of clot solubility test and enzyme-linked immunosorbent assay, respectively. Variations were detected by direct sequencing of F13A and F13B genes in the pedigree and the unborn fetus. Pathogenicity assessment of variations was based on American College of Medical Genetics and Genomics Guidelines. Results: Ten variants in the F13A gene including a novel missense mutation in exon 10, a nonsense mutation in exon 4, a missense mutation in exon 12, 2 missense mutations in exon 14, 3 polymorphisms in intron 10, 2 polymorphisms in intron 14 were detected. Two variants in the F13B gene including a polymorphism in 3’UTR and a synonymous mutation were detected. The compound heterozygous mutations of the nonsense mutation and a novel missense mutation of the F13A gene caused the deficiency in proband, and the fetus which was evaluated to be unaffected by PND was born successfully and the results were verified by follow-up visits. Discussion: We first established the PND procedure with pathogenicity assessment in FXIIID patients. The F13A gene mutations’ spectrum of the Chinese Han population was enriched.
机译:目的:迫切需要建立产前诊断(PND)程序,以便及时处理和预防XIII因子缺乏症(FXIIID)的致命后果,而且中国人之间的变异数据非常少。我们的目的是在中国人中发现一个新的突变,并建立具有病原性分析的快速精确的PND程序,以有助于预防孕妇的产后出血和新生儿的中枢神经系统出血。方法:分别通过凝块溶解度试验和酶联免疫吸附试验的定性和定量试验对FXIIID进行诊断。通过对家系和未出生胎儿中的F13A和F13B基因进行直接测序来检测变异。变异的致病性评估基于美国医学遗传学和基因组学指南。结果:F13A基因的十个变异包括第10外显子的新的错义突变,第4外显子的无义突变,第12外显子的错义突变,第14外显子的错义突变,内含子10的3个多态性,内含子14的2个多态性。检测到。检测到F13B基因的两个变体,包括3'UTR中的多态性和同义突变。无意义突变的复合杂合突变和F13A基因的新的错义突变导致先证者的缺陷,被评估为不受PND影响的胎儿成功出生,并通过后续随访证实了结果。讨论:我们首先建立了FXIIID患者的PND程序,并进行了致病性评估。中国汉族人群的F13A基因突变谱得到了丰富。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号